Direct interleukin-6 inhibitor olokizumab in the treatment of polymyalgia rheumatica: a case series.

To describe the experience of using olokizumab (OKZ) in patients with polymyalgia rheumatica (PMR) who have contraindications or an inadequate response to methotrexate and require steroid-sparing therapy, and to analyze treatment outcomes in this cohort. A case series included 23 patients with PMR [including giant-cell arteritis (GCA) in 9 patients] treated with OKZ. The assessment of disease activity was carried out using the PMR-activity score (AS) index, as well as laboratory parameters [erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)]. The statistical analysis was performed using the StatTech v program. 4.7.3. Olokizumab therapy resulted in a significant decrease in PMR activity: the PMR-AS index decreased from 18.6 (14.2-24.4) to 3.01 (1.62-6.09) points by 12-24th weeks. Most patients (86.3%) who received therapy achieved remission or low disease activity. Laboratory parameters have also improved: ESR values decreased from 32.00 (20.00-47.00) to 7.00 (5.00-8.50) mm/h, and CRP - from 14.10 (8.10-40.80) to 0.85 (0.30-2.15) mg/l. The steroid dose decreased from 7.5 (5.0-15.0) to 2.50 (0.00-2.50) mg/day by week 24. The results listed above were statistically significant (p < 0.05). The disease duration of less than 36 months at the time of initiation of therapy proved to be a significant predictor of achieving low PMR activity (AUC = 0.912; p = 0.024). Olokizumab demonstrated high efficacy in reducing the activity of PMR, laboratory markers of inflammation and the dose of steroids in patients with inefficacy or intolerance to methotrexate.